Conference
Validated five-factor prognostic model for survival of patients (pts) with metastatic urothelial carcinoma (mUC) receiving different post-platinum PD-L1 inhibitors.
Abstract
476
Background: A prognostic model for overall survival (OS) of mUC was previously reported in the setting of post-platinum atezolizumab (Pond GR, GU ASCO 2018). This model was limited by employing only atezolizumab treated pts, small size of the validation dataset and unclear applicability to other PD-1/L1 inhibitors. Hence, we constructed a robust prognostic model utilizing the combined atezolizumab cohort as the discovery …
Authors
Sonpavde G; Hennessy D; Manitz J; Niegisch G; Powles T; Rosenberg JE; Bajorin DF; Apolo AB; Pond GR
Volume
37
Pagination
pp. 476-476
Publisher
American Society of Clinical Oncology (ASCO)
Publication Date
March 1, 2019
DOI
10.1200/jco.2019.37.7_suppl.476
Conference proceedings
Journal of Clinical Oncology
Issue
7_suppl
ISSN
0732-183X